ResearcherStiftung CharitéNo recent work listed
Petra M. Schulz
Matched on ORCID iD 0000-0002-6765-6659; OpenAlex author ID A5056859506. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2011: 1 paper · 2012: 2 papers
Papers 3
- The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer. First author DOI 10.1038/bjc.2011.521↗
- Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells. Co-author DOI 10.1111/j.1349-7006.2011.02140.x↗
- Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. Co-author DOI 10.1096/fj.11-182287↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Bertram J. Wiedenmann · 3 shared papers, 2011–2012 · strength 0.09
- Paper The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer. DOI 10.1038/bjc.2011.521↗
- Paper Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells. DOI 10.1111/j.1349-7006.2011.02140.x↗
- Paper Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. DOI 10.1096/fj.11-182287↗
- Katharina M Detjen · 3 shared papers, 2011–2012 · strength 0.09
- Paper The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer. DOI 10.1038/bjc.2011.521↗
- Paper Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells. DOI 10.1111/j.1349-7006.2011.02140.x↗
- Paper Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer. DOI 10.1096/fj.11-182287↗
- Noreen Otto · 2 shared papers, 2012 · strength 0.07
- Arne Scholz Scholz · 2 shared papers, 2011–2012 · strength 0.06
- Anja Rabien · 1 shared paper, 2012 · strength 0.03
- Frauke Alves · 1 shared paper, 2011 · strength 0.02
- Christian Fischer · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.